Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism
Recruiting now · Not applicable
Conditions studied: Idiopathic Hyperaldosteronism, Hyperaldosteronism
In brief
Idiopathic hyperaldosteronism (IHA) represents about 65% of primary hyperaldosteronism cases. Although mineralocorticoid receptor antagonists (MRAs) are the standard first-line treatment, they are often limited by adverse effects. Superselective adrenal artery embolization (SAAE) has been utilized for IHA over the last decade, yet comparative studies against MRAs are lacking. The objective of this study is to compare the safety and efficacy of SAAE and MRA to determine the feasibility of SAAE in treating IHA.
Key facts
- Study ID
- NCT07328230
- Run by
- Chinese Academy of Medical Sciences, Fuwai Hospital
- People needed
- 172
- Starts
- 2022-08-01
- Expected to finish
- 2025-12-31
- Last updated by the study team
- 2026-01-09
Who can join
Age: 15 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Aged from 15 to 60 with no limits in sex;
- Patients are diagnosed with primary aldosteronism according to the criteria of the 2016 Endocrine Society guidelines;
- Sub-typing diagnosis confirmed idiopathic hyperaldosteronism;
- Patients or their legal representatives have to sign written informed consent approved by the ethics committee.
You may not qualify if…
- Unilateral adrenal hyperplasia;
- Renal insufficiency with an estimated glomerular filtration rate (based on the modification of diet in renal disease criteria) <45 ml/min/1.73 m², and/or serum creatinine >176 μmol/L；
- Hemorrhagic or ischemic stroke, endovascular stent implantation and myocardial infarction within the previous 3 months;
- Severe contrast agent allergy;
- Women who are pregnant or planning to become pregnant;
- Patients with other serious organic diseases cannot tolerate SAAE treatment;
- Other forms of secondary hypertension.
Where it is running
- Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, Beijing Municipality, China (enrolling)
- Second Affiliated Hospital of Nanchang University — Nanchang, Jiangxi, China (enrolling)
- The First Affiliated Hospital of Chengdu Medical College — Chengdu, Sichuan, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.